// App-Quantinova.ai

395 : Influence of baseline OFF-time in the efficacy response of opicapone in Parkinson’s disease patients with motor fluctuations: The BIPARK-I double-blind experience

Researchers

Presenter

  • P. Korlipara

Principal Investigators

  • J. Ferreira

  • H. Gama

  • A. Santos

  • F. Ikedo

  • E. Arbe

  • J-F. Rocha

  • P. Soares-da-Silva

Medical Centers

  • N/A

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Parkinson's disease

Biomarkers

  • Monoamine oxidase B

Drug/Treatment

  • entacapone

  • Levodopa

  • Dopamine hydrochloride

Outcome

  • N/A

Study Design

  • Placebo Control

  • Double Blind/Blinded

  • Multinational

  • Multicenteric

  • Controlled

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved